Government Agencies FDA


  • pfizer_logo_new_200.jpg

    Newly released documents reveal that Pfizer presented a study falsely claiming that its arthritis drug, Celebrex, was safer on the stomach than competing drugs, the New York Times reports. 

  • factory-worker2-200.jpg

    U.S. regulators, retailers and manufacturers are growing increasingly concerned that a surge in the number of products being recalled is resulting in "fatigue" by the public — increasing the chance that consumers could ignore or miss a recall that could ultimately endanger their health, USA Today reports.

  • Onyx Pharma CEO on New Cancer Drug Monday, 4 Jun 2012 | 4:40 PM ET
    Onyx Pharma CEO on New Cancer Drug

    Anthony Coles, Onyx Pharmaceuticals president/CEO, discusses the status of his company's latest drugs.

  • salmon_whole_fish_200.jpg

    If Americans ever eat genetically engineered fast-growing salmon, it might be because of a Soviet biologist turned oligarch turned government minister turned fish farming entrepreneur, the New York Times reports.

  • Jefferies Upgrades Arena Pharmaceuticals to 'Buy' Friday, 11 May 2012 | 1:19 PM ET
    Jefferies Upgrades Arena Pharmaceuticals to 'Buy'

    CNBC's Seema Mody reports on the latest details of the FDA advisory panel's review of Arena Pharmaceuticals' anti-obesity drug.

  • GNC, Vitamin Shoppe Keep DMAA Products in Stores Tuesday, 8 May 2012 | 11:43 AM ET

    Ten days after the FDA sent warning letters to manufacturers of supplements with DMAA in it, the nation’s largest supplement retailers still have the product on the shelves.

  • DMAA

    In a wake of a warning letter sent to them by the FDA, some companies whose pre-workout or weight loss products include the ingredient DMAA, are starting to move on with life without it.

  • A warning letter written by the Food & Drug Administration last week to ten companies that produce pre-workout supplements with the ingredient dimethylamyamine (DMAA) has sent shockwaves through the industry, not only to the producers of the products but to consumers who have taken them.

  • Supplement Stir: DMAA Tuesday, 1 May 2012 | 3:40 PM ET
    Supplement Stir: DMAA

    CNBC's Darren Rovell reports on how shares of GNC Holdings and Vitamin Shoppe are holding up since announced they will be pulling products containing DMAA.

  • Pulling DMAA Products Tuesday, 1 May 2012 | 2:56 PM ET Pulling DMAA Products

    CNBC's Darren Rovell reports is pulling all products containing DMAA, an ingredient the FDA stated does not derive from a plant.

  • Eli Lilly's CEO on Prescription for Profits Wednesday, 25 Apr 2012 | 7:10 AM ET
    Eli Lilly's CEO on Prescription for Profits

    John Lechleiter, Eli Lilly chairman & CEO breaks down his company's earnings results of an adjusted $0.92 a share versus estimates of $0.78 est. and a look at the drug maker's generic challenges, and the politics of prescriptions.

  • Hedge Funds, Banks Avoid New Derivatives Rules Wednesday, 18 Apr 2012 | 11:48 AM ET
    NYSE traders

    U.S. securities regulators on Wednesday finalized long-awaited rules that will dictate which companies dealing in derivatives will be subject to costly capital, margin and business conduct requirements.

  • Alzheimer Early Detection & the FDA Monday, 9 Apr 2012 | 2:51 PM ET
    Alzheimer Early Detection & the FDA

    CNBC's Seema Mody reports on a major development in the early detection of Alzheimer's disease, and discussing how the FDA approved brain scan from Eli Lilly works, with Robert Petersen, M.D., Mayo Clinic.

  • Last Call: Taking Burger King Public Again Tuesday, 3 Apr 2012 | 10:21 PM ET

    Sharpen your pencils, it's Last Call quiz time.

  • Tobacco Companies Dodge Graphic Packaging Requirement Wednesday, 29 Feb 2012 | 4:00 PM ET
    Marlboro Cigarettes

    A federal requirement would have begun forcing U.S. tobacco companies to put large graphic images on their cigarette packages, until a judge blocked the ruling Wednesday. 

  • Vivus CEO Optimistic On FDA Approval for Qnexa Monday, 27 Feb 2012 | 5:08 PM ET

    Vivus CEO Leland Wilson saw “a very powerful signal” that anti-obesity drug Qnexa would be approved.

  • Vivus CEO Expects FDA Approval in April Monday, 27 Feb 2012 | 12:29 PM ET
    Vivus CEO Expects FDA Approval in April

    Leland Wilson, Vivus CEO, discusses the optimist outlook for his company after an FDA panel backed its new diet drug, Qnexa; marketing strategies for the new product; and whether his company is now a potential takeover target, with the Fast Money traders.

  • Making Money Without the Speculation Rush Friday, 24 Feb 2012 | 5:32 PM ET

    Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.

  • Can Drugs Fight Obesity? FDA Weighs In Friday, 24 Feb 2012 | 4:45 PM ET
    Can Drugs Fight Obesity? FDA Weighs In

    There will be no silver bullet to reduce obesity, says Margaret Hamburg, FDA commissioner. Adding that, "generic drugs make a huge difference in patient care."

  • FDA’s Margaret Hamburg Takes On Drug Shortages Friday, 24 Feb 2012 | 1:19 PM ET
    Margaret Hamburg, MD and Commissioner of FDA

    Generic drugs are in focus at Generic Pharmaceutical Association's annual meeting in Orlando, Florida. The hot button issue: backlog of generic drug applications at the Food & Drug Administration.